New therapies for the treatment of age-related macular degeneration

Bibliography

• NATIONAL SOCIETY TO PREVENT BLINDNESS: Visual problems in the United States: definitions, data sources, detailed data tables, analyses, interpretation. National Society to Prevent Blindness, New York, USA (1980):1–46.
   Google Scholar
• KLEIN R, KLEIN BEK, LINTON KLP: Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology (1992) 99:933–943.
   PubMed Web of Science ®Google Scholar
• STRAMM LE: Synthesis and secretion of glycosamino-glycans in cultured retinal pigment epithelium. Invest. Ophthalmol Vis. Sci. (1987) 28:618–627.
   PubMed Web of Science ®Google Scholar
• BOK D: Processing and transport of retinoids by the retinal pigment epithelium. Eye (1990) 4:326–332.
   PubMed Web of Science ®Google Scholar
• CLARK VM: The cell body of the retinal pigment epithe-lium. In: The Retina. A Model for Cell Biology Studies: Part II Adler R, Farber D (Eds.), Academic Press, Orlando, FL, USA (1986) :129–168.
   Google Scholar
• YOUNG RW, BOK D: Participation of the retinal pigment epithelium in the rod outer segment renewal process. J. Cell Biol. (1969) 42:392–403.
   PubMed Web of Science ®Google Scholar
• FINE BS, YANOFF M: The retina. In: Ocular Histology. A Text and Atlas. Fine BS, Yanoff M (Eds.), Harper & Row, New York (1972):47–107.
   Google Scholar
• NUSSBAUM JJ, PRUETT RC, DELORI FC: Historic perspec-tives. Macular yellow pigment. The first 200 years. Retina (1981) 1:296–310.
   Google Scholar
• BRESSLER SB, MAGUIRE MG, BRESSLER NM et al.: The Macular Photocoagulation Study Group: relationship of drusen and abnormalities of the retinal pigment epithelium to the prognosis of neovascular macular degeneration. Arch. Ophthalmol. (1990) 108:1442–1447.
   PubMed Web of Science ®Google Scholar
• EL BABA, GREEN WR, FLEISCHMANN J et al.: Clinicopa-thologic correlation of lipidization and detachment of the retinal pigment epithelium. Am. J. Ophthalmol (1986) 101:576–583.
   PubMed Web of Science ®Google Scholar
• GREEN WR, MCDONNELL PJ, YEO JH: Pathologic features of senile macular degeneration. Ophthal-mology (1985) 92:615–627.
   PubMed Web of Science ®Google Scholar
• ••An excellent description of the pathologic changes inARMD.
   Google Scholar
• GREEN, WR, ENGER C: Age-related macular degenera-tion histopathologic studies: the 1992 Lorenz E. Zimmerman Lecture. Ophthalmology (1993) 100:1519–1535.
   Google Scholar
• BRESSLER NM, SILVA JC, BRESSLER SB et al.: Clinicopa-thologic correlation of drusen and retinal pigment epithelial abnormalities in age-related macular degeneration. Retina (1994) 14:130–142.
   PubMed Web of Science ®Google Scholar
• ••An excellent clinicopathologic study of ARMD.
   Google Scholar
• SARKS SH: Aging and degeneration in the macular region: a clinicopathologic study. Br. J. Ophthalmol. (1976) 60:324–341.
   PubMed Web of Science ®Google Scholar
• YOUNG RW: Solar radiation and age-related macular degeneration. Sun'. Ophthalmol. (1988) 32:252–269.
   PubMed Web of Science ®Google Scholar
• GOTTSCH JD, BYNOE LA, HARLAN JB: Light-induced deposits in Bruch's membrane of protoporphyric mice. Arch. Ophthalmol. (1993) 111:126–129.
   PubMedGoogle Scholar
• WEST SK, ROSENTHAL FS, BRESSLER, NM et al.: Exposure to sunlight and other risk factors for age-related macular degeneration. Arch. Ophthalmol. (1992) 110:99–104.
   PubMedGoogle Scholar
• TAYLOR HR, WEST S, MUNOZ B et al: The long-term effects of visible light on the eye. Arch. Ophthalmol (1992) 110:99–104.
   PubMed Web of Science ®Google Scholar
• CRUICKSHANKS KJ, KLEIN R, KLEIN BEK: Sunlight and age-related macular degeneration: The Beaver Dam Eye Study. Arch. Ophthalmol (1993) 111:514–518.
   PubMed Web of Science ®Google Scholar
• HYMAN LG, LILIENFELD AM, FERRIS FL, FINE SL: Senile macular degeneration: a case control study. Am. J. Epidemiol. (1983) 118:213–227.
   PubMed Web of Science ®Google Scholar
• BLUMENKRANZ MS, RUSSELL SR, ROBEY MG et al: Risk factors in age-related maculopathy complicated by choroidal neovascularization. Ophthalmology (1986) 96:552–558.
   Google Scholar
• KLEIN R, KLEIN BEK, LINTON KLP, DEMETS DL: TheBeaver Dam Eye Study: the relationship of age-related maculopathy to smoking. Am. J. Epidemiol. (1993) 137:190–200.
   PubMed Web of Science ®Google Scholar
• GOLDBERG J, FLOWERDEW G, SMITH E et al.: Factorsassociated with AMD: analysis of the first NHANES. Am. Epidemiol. (1988) 128:700–710.
   PubMed Web of Science ®Google Scholar
• •A description of factors associated with ARMD.
   Google Scholar
• THE EYE DISEASE CASE-CONTROL STUDY GROUP: Antioxidant status and neovascular age-related macular degeneration. Arch. Ophthalmol (1993) 111:104–109.
   PubMedGoogle Scholar
• •Describes the relationship between anti-oxidants and neovascular ARMD.
   Google Scholar
• SEDDON JM, AJANI UA, SPERDUTO RD et al: Dietarycarotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. JAMA (1994) 272:1413–1420.
   PubMed Web of Science ®Google Scholar
• NEWSOME DA, SWARTZ M, LEONE NC et al.: Oral zinc inmacular degeneration. Arch. Ophthalmol. (1988) 106:192–198.
   PubMed Web of Science ®Google Scholar
• THE EYE DISEASE CASE-CONTROL STUDY GROUP: Risk factors for neovascular age-related macular degenera-tion. Arch. Ophthalmol (1992) 110:1701–1708.
   PubMed Web of Science ®Google Scholar
• •Describes some of the risk factors for developing neovascu-lar ARMD.
   Google Scholar
• STUR M, TITTL M, REITNER A, MEISINGER V: Oral zinc and the second eye in age-related macular degenera-tion. Invest. Ophthalmol. Vis. Sci. (1996) 37:1225–1235.
   PubMedGoogle Scholar
• MACULAR PHOTOCOAGULATION STUDY GROUP: Recurrent choroidal neovascularization after argon laser photocoagulation for neovascular lesions of neovascular maculopathy. Results of a randomized clinical trial. Arch. Ophthalmol. (1986) 104:503–512.
   PubMed Web of Science ®Google Scholar
• MACULAR PHOTOCOAGULATION STUDY GROUP: Subfoveal neovascular lesions in age-related macular degeneration: guidelines for evaluation and treatment in the Macular Photocoagulation Study. Arch. Ophthalmol. (1991) 109:1242–1257.
   PubMed Web of Science ®Google Scholar
• MACULAR PHOTOCOAGULATION STUDY GROUP: Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Arch. Ophthalmol. (1991) 109:1220–1231.
   PubMed Web of Science ®Google Scholar
• MACULAR PHOTOCOAGULATION STUDY GROUP: Laser photocoagulation of subfoveal neovascular recurrent neovascular lesions in age-related macular degenera-tion. Results of a randomized clinical trial. Arch. Ophthalmol (1991) 109:1232–1241.
   PubMedGoogle Scholar
• MACULAR PHOTOCOAGULATION STUDY GROUP: Occult choroidal neovascularization. Influence on visual outcome in patients with age-related macular degeneration. Arch. Ophthalmol. (1996) 114:400–412.
   Google Scholar
• THOMAS MA, GRAND MG, WILLIAMS DF et al.: Surgical management of subfoveal choroidal neovasculariza-tion. Ophthalmology (1992) 99:952–968.
   PubMed Web of Science ®Google Scholar
• ••Describes submacular surgery for the treatment of subfovealchoroidal neovascularisation.
   Google Scholar
• BERGER AS, KAPLAN HJ: Clinical experience with the surgical removal of subfoveal neovascular membranes. Ophthalmology (1992) 99:969–976.
   PubMed Web of Science ®Google Scholar
• LAMBERT HM, CAPONE A, AABERG TM et al.: Surgical excision of subfoveal neovascular membranes in age-related macular degeneration. Am. J. Ophthalmol (1992) 114:241–242.
   PubMed Web of Science ®Google Scholar
• ORMEROD LD, PUKLIN JE, FRANK RN: Long-term outcomes after the surgical removal of advanced subfoveal neovascular membranes in age-related macular degeneration. Ophthalmology (1 9 9 4) 101:1201-1210.
   Google Scholar
• HAWKINS BS FOR THE SUBMACULAR SURGERY TRIALS PLANNING GROUP: Visual acuity outcomes following submacular surgery, laser photocoagulation, or observation of subfoveal choroidal neovasculariza-tion. Invest. Ophthalmol. Vis. Sci. (1995) 36(Suppl.):9.
   Google Scholar
• BERGINK GJ, DEUTMAN AF, VAN DEN BROEK JE et al.: Radiation therapy for subfoveal choroidal neovascu-lar membranes in age-related macular degeneration. A pilot study. Doc. Ophthalmol. (1995) 90:67–74.
   Google Scholar
• FINGER PT, BERSON A, SHERR D et al.: Radiation therapy for subretinal neovascularization. Ophthalmology (1996) 103:878–889.
   PubMed Web of Science ®Google Scholar
• FRIERICHSEN EJ, REDLANDS CA, ALATER JD: Protonbeam irradiation of subfoveal choroidal neovasculari-zation in age-related macular degeneration. Invest. Ophthalmol Vis. Sci. (1995) 34 (Suppl.) :171.
   Google Scholar
• MANDAI, M, OGURA Y, TANIGUMICHI T: The effect ofradiation therapy on subfoveal choroidal neovascular membrane in patients with ARMD. Invest. Ophthalmol Vis. Sci. (1995) 34(Suppl.):146.
   Google Scholar
• THE RADIATION THERAPY FOR AGE-RELATED MACULAR DEGENERATION (RAD) STUDY GROUP: A prospective, randomized, double-masked trial on radiation therapy for neovascular age-related macular degeneration (RAD Study). Ophthalmology (1999) 106:2239–2247.
   PubMed Web of Science ®Google Scholar
• ••A study describing the utility of radiation therapy inneovascular ARMD.
   Google Scholar
• GABRIELIAN K, OGANESIAN A, PATEL SC et al.: Cellular response in rabbit eyes after human fetal RPE transplantation. Graefes Arch. Clin. Exp. Ophthalmol (1999) 237:326–335.
   PubMed Web of Science ®Google Scholar
• OGANESIAN A, GABRIELIAN K, ERNEST JT, PATEL SC: A new model of retinal pigment epithelium transplanta-tion with microspheres. Arch. Ophthalmol. (1999) 117:1192–1200.
   PubMedGoogle Scholar
• •An interesting study describing the transplantation of foetal RPE cells.
   Google Scholar
• MILLER JW, WALSH AW, KRAMER M et al.: Photodynamic therapy of experimental choroidal neovascularization using lipoprotein-derived benzoporphyrin. Arch. Ophthalmol (1995) 113:810–818.
   PubMed Web of Science ®Google Scholar
• MILLER H, MILLER B: Photodynamic therapy of subretinal neovascularization in the monkey eye. Arch. Ophthalmol. (1993) 111:5855–5860.
   Google Scholar
• MILLER JW, SCHMIDT-ERFURTH U, SICKENBERG M et al: Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: Results of a single treatment in a Phase 1 and 2 study. Arch. Ophthalmol. (1999) 117:1161–1173.
   PubMedGoogle Scholar
• ••Describes treatment parameters and results for singlephotodynamic therapy treatments with the compound verteporfin.
   Google Scholar
• SCHMIDT-ERFURTH U, MILLER JW, SICKENBERG M et al.: Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a Phase 1 and 2 study. Arch. Ophthalmol. (1999) 117:1174–1184.
   Google Scholar
• ••Describes the results of photodynamic therapy retreatmentswith the compound verteporfin.
   Google Scholar
• TREATMENT OF AGE-RELATED MACULAR DEGENERA-TION WITH PHOTODYNAMIC THERAPY (TAP) STUDY GROUP: Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degenera-tion with verteporfin: one year results of 2 random-ized clinical trials - TAP report 1. Arch. Ophthalmol (1999) 117:1329–1345.
   PubMedGoogle Scholar
• ••Describes the results of photodynamic therapy for subfovealchoroidal neovascularisation.
   Google Scholar
• MILLER JW, STINSON WG, FOLKMAN J: Regression of experimental iris neovascularization with systemic alpha-interferon. Ophthalmology (1993) 100:9–14.
   PubMed Web of Science ®Google Scholar
• EZEKOWITZ RAB, MULLIKEN JB, FOLKMAN J: Interferon a-2a for life threatening hemangiomas of infancy. N Engl. J. Med. (1992) 326:1459–1463.
   Web of Science ®Google Scholar
• FUNG WE: Interferon a-2a for treatment of age-related macular degeneration. Am. J. Ophthalmol. (1992) 112:349–350.
   Web of Science ®Google Scholar
• ENGLER CB, SANDER B, DOEFOED P et al.: Interferona-2a treatment of patients with subfoveal neovascular macular degeneration. A pilot investigation. Acta Ophthalmol (1993) 71:27–31.
   PubMed Web of Science ®Google Scholar
• THOMAS MA, IBANEZ HE: Interferon a-2a in thetreatment of subfoveal choroidal neovascularization. Am. J. Ophthalmol. (1993) 115:563–568.
   PubMed Web of Science ®Google Scholar
• GUYER DR, ADAMIS AP, YANNUZZI LA et al. Interferon a-2a is ineffective for patients with choroidal neovascularization secondary to age-related macular degeneration: results of a prospective randomized placebo-controlled clinical trial. Arch. Ophthalmol (1997) 115:865–872.
   PubMedGoogle Scholar
• SHWEIKI D, ITIN A, SOFFER D, KESHET E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia initiated angiogenesis. Nature (1992) 359:843–845.
   PubMed Web of Science ®Google Scholar
• ••An excellent paper describing the relationship betweenhypoxia, VEGF expression and neovascularisation.
   Google Scholar
• MILLER J, ADAMIS AP, SHIMA DT et al.: Vascular endothe- lial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am. J. Pathol (1994) 145:574–584.
   PubMed Web of Science ®Google Scholar
• ADAMIS AP, MILLER J, BERNAL M et al.: Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retino-pathy. Am. J. Ophthalmol. (1994) 118:445–450.
   PubMed Web of Science ®Google Scholar
• ADAMIS AP, SHIMA DT, TOLENTINO M et al.: Inhibition of VEGF prevents retinal ischemia-associated iris neovascularization in a primate. Arch. Ophthalmol (1995) 114:66–71.
   Google Scholar
• TOLENTINO MT, MILLER JW, GRAGOUDAS ES et al.: Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a non-human primate. Arch. Ophthalmol (1996) 114:964–970.
   PubMed Web of Science ®Google Scholar
• STONE EM, LOTERY AJ, MUNIER FL et al.: A single EFEMP1 mutation associated with both Malattia Leventinese and Doyne honeycomb retinal dystrophy. Nature Genetics (1999) 22:199–202.
   PubMed Web of Science ®Google Scholar